The Loss-of-Exclusivity Playbook in Saudi Arabia

Governing thought: In Saudi Arabia, loss of exclusivity (LOE) no longer just erodes price — it threatens access . And the defence is no longer just discounting — it's localization .

The MSD sitagliptin franchise is the clearest worked example on the board, and it's a preview of what a dozen more multinationals will face in the next 24–36 months.

1. The case: a franchise that's shrinking in value while holding in volume

The asset is still large. In 2024, MSD's Januvia + Janumet franchise in Saudi Arabia was ~3.4 million packs and SAR 323M (~USD 86M) — one of the Kingdom's biggest single-molecule diabetes franchises. [DATA: IQVIA Saudi]

But value is collapsing while volume holds — the single most important fact in this case

Units: +1.1% CAGR 2020–24 , still ~4% above 2020 .

Value: −5.5% CAGR , with a −26% fall in 2024 alone against a unit fall of only −15% . [DATA]

That divergence — units flat, value falling away beneath them — is the "scissors" in Chart 1 . It tells you this is not a demand problem. It's a price problem.

The price cliff confirms it. Realised price per pack was flat for three years, then fell off a cliff: Januvia SAR 122 → 91 (−25%) and Janumet SAR 131 → 102 (−22%) , almost entirely in 2023–24 ( Chart 2 ). [DATA]

Why then? Because that's exactly when sitagliptin genericized internationally. Merck's sitagliptin compound patent expired January 2023 (US) — but exclusivity fell earlier in ex-US markets: China (July 2022), the EU (September 2022) , with worldwide Januvia/Janumet sales down 28% as generics entered "most markets in Europe and Asia Pacific." [SOURCED: Merck 10-Q/10-K] The Saudi 2023–24 price collapse is the local fingerprint of that global wave, compounded by SFDA/NUPCO reference-price resets.

2. The defensive playbook — why localization, not discounting, is the answer

Here's the strategic core. In most markets, an originator facing LOE defends with price. In Saudi Arabia, price alone is a losing fight — because the buyer structure changes what "defence" means.

The government is the buyer that matters. Public procurement, run through NUPCO (PIF-owned, centralized), is 54% of the ~SAR 30bn Saudi pharmaceutical market — the single most powerful buyer in the Kingdom, controlling 400+ public facilities.

And NUPCO has weaponized localization. Its 2026 tender framework embeds a 15% "Made in Saudi" (MiS) localization score , and — critically — once a compliant locally-manufactured product exists, foreign equivalents can be excluded from the tender entirely. Importing is no longer enough to stay eligible.

That reframes MSD's Dammam Pharma localization of Januvia/Janumet. It isn't (only) Vision-2030 goodwill — it's the rational defence of a genericizing franchise in its most important channel : [EPT VIEW, grounded in the sourced mechanism]

Tender protection. Local manufacture converts a losing price fight into MiS-scored eligibility — keeping the product on the NUPCO shelf instead of excluded when a local generic appears.

Cost structure. Local fill-finish strips out import duty, freight, FX and lead time — enough to bid at post-LOE prices while defending gross margin, and to avoid the supply-failure penalties tenders impose.

Lifecycle switch. The only growing line in the entire franchise is Janumet XR — from zero in 2020 to ~100K packs / SAR 14.6M in 2024 (+58% YoY) . [DATA] A local plant supports migrating the franchise to XR, where generic competition hasn't yet arrived.

Durable base. Saudi adult diabetes prevalence is ~18–20% [SOURCED: IDF-range] with a young, insured, growing population; sitagliptin + metformin remains core second-line therapy. The volume base justifies a dedicated local line for a decade.

The pattern: localization has become a lifecycle-defence instrument , not just an industrial-policy box. You don't localize your growth products — you localize the ones under generic siege, to defend the access you already hold.

3. What comes next — the multinationals facing the same reckoning

MSD is not an outlier. It's the leading edge of a documented 2026–2028 global patent cliff that will land in Saudi Arabia — often earlier than in the US, exactly as sitagliptin did (US 2026, but EU/China 2022).

Blockbusters and classes to watch as they genericize regionally [SOURCED for the cliff; EPT VIEW for the KSA response] :

Molecule (brand) Owner Class Regional relevance

Semaglutide (Ozempic) Novo Nordisk GLP-1 / diabetes-obesity Massive GCC demand; the highest-stakes cliff

Apixaban (Eliquis) BMS / Pfizer Anticoagulant / CV High government-channel volume

Tofacitinib (Xeljanz) Pfizer Immunology Specialty tender exposure

Pembrolizumab (Keytruda) Merck Oncology (2028) The largest single franchise globally

Various DPP-4s, statins, ARBs Multiple CV-metabolic Already mid-erosion

EPT's expectation: every multinational with a high-volume, government-channel-dependent blockbuster approaching LOE in the Kingdom will face the same units-hold / value-collapse signature — and will reach the same conclusion MSD did. Expect a wave of "localize-to-defend" moves : originators partnering with Saudi CMOs (Dammam Pharma, SPIMACO, and peers) or committing to Sudair/MODON greenfields under LCGPA's Economic Participation Program, specifically to keep genericizing blockbusters inside NUPCO eligibility. [EPT VIEW]

The through-line across your tracker becomes clear: the patent cliff and the localization drive are the same force viewed from two angles. Generics erode the imported blockbuster; localization is how the originator answers.

4. The GCC dimension — Saudi is the extreme, not the template

Honesty on scope: the hard data here is Saudi Arabia only . The other GCC markets will feel LOE, but differently — and I won't dress inference as data. [EPT VIEW]

Saudi Arabia is the extreme case: a single dominant, PIF-owned buyer (NUPCO) with an explicit localization-exclusion lever. LOE here threatens access , not just price — which is why it triggers manufacturing responses.

UAE, Kuwait, Qatar, Oman, Bahrain are smaller, more private/insurance- and retail-weighted , with less centralized procurement and (mostly) softer local-content exclusion. There, LOE is likely to look more like a conventional generic price-erosion story — value falls, but the localization-or-exit pressure is weaker. The UAE is moving toward its own localization agenda, but without a NUPCO-scale exclusion mechanism.

So the strategic prediction differs by market: in Saudi Arabia, expect localization; across the rest of the GCC, expect price competition and portfolio pruning — with localization following only where local-content rules harden. [EPT VIEW]

5. Implications

For multinationals: in Saudi Arabia, treat LOE and localization as a single decision. The blockbuster you're about to lose to generics is precisely the one to localize — not to grow it, but to defend its tender position. Model the CMO/greenfield decision before the price cliff, not after.

For Saudi manufacturers (Avalon, Tabuk Pharma, SPIMACO, Jamjoom, et al.): the patent cliff is an inbound pipeline of CMO and tech-transfer mandates from originators who suddenly need a local footprint. LOE defence is a business line.

For the region: LOE is quietly accelerating localization more effectively than any incentive — because it converts "should we make it here?" into "we lose the tender if we don't."